Previous 10 | Next 10 |
2023-09-07 07:02:05 ET More on Hepion Pharmaceuticals Hepion Pharma NASH candidate meets phase 2 goal; up 68% Hepion climbs 39% on pre-clinical data for lead asset Hepion granted 180-day extension by Nasdaq to meet bid price requirements For furth...
EDISON, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-assisted therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH...
American Bio Medica Corp. (ABMC) is expected to report for Q1 2024 Fonar Corporation (FONR) is expected to report for Q1 2024 Bank Hapoalim B.M. ADR (BKHYY) is expected to report for Q2 2023 QualTek Services Inc. (QTEKQ) is expected to report for Q2 2023 BIMI International Medical...
Hepion Pharmaceuticals Inc. (HEPA) is expected to report $-2.94 for Q2 2023
- Preclinical studies demonstrate rencofilstat may protect against NASH/NAFLD, shift the liver transcriptome and lipidome toward NASH resolution – - Cyclophilin B inhibition confirmed as an important target for treatment of NAFLD/NASH - EDISON, N.J., June 15, 2023 (GLOBE NE...
EDISON, N.J., June 15, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of fibrotic diseases, including non-alcoholic steato...
2023-05-26 11:27:39 ET Summary Shares of Hepion Pharmaceuticals more than doubled in value after reporting positive data from their phase 2 data evaluating rencofilstat as a NASH therapy. Since then, the stock has fallen greatly as the market has digested the results. Hepion...
EDISON, N.J., May 24, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on artificial Intelligence (“AI”)-assisted therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH ...
2023-05-23 13:09:12 ET Gainers: CohBar ( CWBR ) +158% . Shuttle Pharmaceuticals ( SHPH ) +121% . Ocean Biomedical ( OCEA ) +108% . HeartCore Enterprises ( HTCR ) +110% . Lifecore Biomedical ( LFCR ) +66% . T Stamp ( IDAI ...
2023-05-23 08:45:00 ET Biocept ( BIOC ) 10% . Microvast Holdings ( MVST ) -20% plunges as Energy Department said to cancel DoE contract. Wave Life Sciences ( WVE ) -13% crashes on decision to drop neurology asset on trial setback. ToughBuilt I...
News, Short Squeeze, Breakout and More Instantly...
Hepion Pharmaceuticals Inc. Company Name:
HEPA Stock Symbol:
NASDAQ Market:
Hepion Pharmaceuticals Inc. Website:
Gaucho Group Holdings Inc. (VINO) is expected to report for Q1 2024 Tosoh Corporation (TOSCF) is expected to report for Q4 2024 Adidas AG ADR - Level I (ADDYY) is expected to report $0.69 for Q1 2024 MicroCloud Hologram Inc. (HOLO) is expected to report for Q1 2024 Universal Enter...
Jet.AI Inc. (JTAI) is expected to report for Q1 2024 Forian Inc. (FORA) is expected to report $-0.02 for Q1 2024 Square Enix Holdings Co. Ltd (SQNXF) is expected to report for Q4 2024 Qutoutiao Inc. (QTT) is expected to report for Q4 2023 Molecular Partners AG (MOLN) is expected t...
A look at the top 10 most actives in the United States AGBA Group Holding Limited (AGBA) rose 100.0% to $2.5 on volume of 201,539,290 shares PROSHARES TRUST (SQQQ) fell 2.9% to $12.47 on volume of 154,254,858 shares Tesla Inc. (TSLA) fell 3.4% to $142.05 on volume of 106,267,579 shares ...